Ofatumumab in diffuse large B cell lymphoma?

Abstract

In this issue of Blood, Matasar and colleagues report the results of salvage treatments with anti-CD20 ofatumumab in combination with ifosfamide, carboplatinum, etoposide (ICE) or dexamethasone, high-dose cytarabine, cisplatin (DHAP) in relapsed refractory diffuse large B-cell lymphoma (DLBCL) before transplantation. They conclude that replacing rituximab with ofatumumab in second-line therapy is a promising approach. Copyright © 2011 by The American Society of Hematology; all rights reserved.